Sativex: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

27 March 2024

21 March 2024

  • curprev 04:1404:14, 21 March 2024‎ Lazy talk contribs‎ 1,290 bytes +1,290‎ Created page with "{{TreatmentInfo |drug_name=Sativex (Nabiximols) |FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis |used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management |clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma |common_side_effects=Fatigue, dizziness, nausea, mouth irritation |OS_with=The 2021 trial reported an increase in..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Sativex"